NovoCure/$NVCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NovoCure
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Ticker
$NVCR
Sector
Primary listing
Employees
1,605
Headquarters
Baar, Switzerland
Website
NovoCure Metrics
BasicAdvanced
$1.4B
-
-$1.22
0.75
-
Price and volume
Market cap
$1.4B
Beta
0.75
52-week high
$20.06
52-week low
$9.82
Average daily volume
2.6M
Financial strength
Current ratio
2.897
Quick ratio
2.509
Long term debt to equity
69.521
Total debt to equity
72.945
Interest coverage (TTM)
-8.70%
Profitability
EBITDA (TTM)
-135.159
Gross margin (TTM)
74.80%
Net profit margin (TTM)
-20.79%
Operating margin (TTM)
-22.63%
Effective tax rate (TTM)
0.02%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-9.06%
Return on equity (TTM)
-38.89%
Valuation
Price to revenue (TTM)
2.101
Price to book
4.08
Price to tangible book (TTM)
4.08
Price to free cash flow (TTM)
-18.191
Free cash flow yield (TTM)
-5.50%
Free cash flow per share (TTM)
-0.679
Growth
Revenue change (TTM)
8.28%
Earnings per share change (TTM)
-21.85%
3-year revenue growth (CAGR)
6.81%
10-year revenue growth (CAGR)
34.80%
3-year earnings per share growth (CAGR)
11.39%
10-year earnings per share growth (CAGR)
-10.41%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
NovoCure News
AllArticlesVideos
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
Business Wire·2 weeks ago
Novocure to Participate in 2026 Leerink Global Healthcare Conference
Business Wire·3 weeks ago
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NovoCure stock?
NovoCure (NVCR) has a market cap of $1.4B as of March 18, 2026.
What is the P/E ratio for NovoCure stock?
The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of March 18, 2026.
Does NovoCure stock pay dividends?
No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of March 18, 2026.
When is the next NovoCure dividend payment date?
NovoCure (NVCR) stock does not pay dividends to its shareholders.
What is the beta indicator for NovoCure?
NovoCure (NVCR) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.